NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated…
Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt…
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of…
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable…
ATLANTA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and…
December 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed…
LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing…
Not for distribution by US newswire or in United States TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD.…
OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for…
ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an…